Amneal Pharmaceuticals Reaps $2.5M in Kentucky Incentives
05/11/2010
"In addition to compelling economic incentives, we recognized that the superb quality and dedication of Glasgow's work force is a key factor in Amneal's reputation for service excellence, so the decision to stay and expand operations in Kentucky was an easy one," said Jim Luce, Amneal executive vice president of sales and marketing.
The Kentucky Economic Development Finance Authority has pre-approved Amneal for tax incentives up to $2.5 million through the Kentucky Business Investment program.
Amneal plans to use the funds to consolidate distribution logistics and sales in a 115,000-square-foot Glasgow facility. It will combine distribution that currently exists in Long Island, New York and Fountain Run, Kentucky. The company develops, manufactures, and distributes generic pharmaceuticals. It is the tenth largest supplier of generic drugs in the country in terms of prescriptions dispensed.
Project Announcements
Certus Medical Expands Ingham County, Michigan, Operations
04/16/2024
Kalmbach Feeds Expands Wyandot County, Ohio, Operations
04/16/2024
Germany-Based Tesa Tape Relocates-Establishes Grand Rapids, Michigan, Headquarters
04/15/2024
FUJIFILM Diosynth Biotechnologies Expands Holly Springs, North Carolina, Operations
04/15/2024
Two Rivers Lumber Plans Coosa County, Alabama, Sawmill Operations
04/15/2024
Protomet Corporation Plans Rockwood, Tennessee, Operations
04/15/2024
Most Read
-
2023's Leading Metro Locations: Hotspots of Economic Growth
Q4 2023
-
2023 Top States for Doing Business Meet the Needs of Site Selectors
Q3 2023
-
38th Annual Corporate Survey: Are Unrealized Predictions of an Economic Slump Leading Small to Mid-Size Companies to Put Off Expansion Plans?
Q1 2024
-
Manufacturing Momentum Is Building
Q1 2024
-
20th Annual Consultants Survey: Clients Prioritize Access to Skilled Labor, Responsive State & Local Government
Q1 2024
-
Making Hybrid More Human in 2024
Q1 2024
-
Public-Private Partnerships Incentivize Industrial Development
Q1 2024